துணை புதியது மருந்து விண்ணப்பம் திட்டமிடப்பட்டுள்ளது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 –
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO ....

United Kingdom , United States , Comunidad Autonoma De Cataluna , Jessica Rennekamp , Holly Manning , Exchange Commission , European Society For Medical Oncology Congress , Corporate Communications , Agios Pharmaceuticals Inc , Supplemental New Drug Application Planned , Agios Pharmaceuticals , American Society , Updated Safety , European Society , Medical Oncology Congress , Lancet Oncology , Interval Prolongation , Prolonging Drugs , Prescribing Information , Private Securities Litigation Reform Act , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜெசிகா றெண்னேகம்பி , ஹோலி மானிங் , பரிமாற்றம் தரகு ,